2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N19941
    Schisanwilsonin K
    		Inhibitor
    Schisanwilsonin K is a dibenzocyclooctane lignan found in the stems of Schisandra wilsoniana with weak anti-HBV activity.Schisanwilsonin K can be used for the research of hepatitis B virus infection.
    Schisanwilsonin K
  • HY-N3093
    Periglaucine B
    		Inhibitor
    Periglaucine B ((+)-Periglaucine B) is an alkaloid and an HBsAg inhibitor. Periglaucine B can be isolated from Pericampylus glaucus. Periglaucine B inhibits the secretion of hepatitis B virus (HBV) surface antigen (HBsAg) in Hep G2.2.15 cells with an IC50 of 0.47 mM.
    Periglaucine B
  • HY-B0250S1
    Lamivudine-13C,15N2,d2
    		Inhibitor
    Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase.
    Lamivudine-<sup>13</sup>C,<sup>15</sup>N<sub>2</sub>,d<sub>2</sub>
  • HY-145049
    HBV-IN-6
    		Inhibitor
    HBV-IN-6 is a potent HBV inhibitor with an EC50 of 44 nM (WO2021213445A1, compound 3).
    HBV-IN-6
  • HY-149468
    Antiviral agent 38
    		Inhibitor
    Antiviral agent 38 (compound 2.1-1) is a potent antiviral agent. Antiviral agent 38 can be used for hepatitis B virus (HBV) research.
    Antiviral agent 38
  • HY-156702
    HBV-IN-38
    		Inhibitor
    HBV-IN-38 (Example 193) is an HBV DNA inhibitor (EC50≤100nM). HBV-IN-38 can be used to study viral infections.
    HBV-IN-38
  • HY-161605
    HBV/HDV-IN-2
    		Inhibitor
    HBV/HDV-IN-2 (Compd 143) is a HBV, HDV and PD-1/PD-L1 inhibitor, with an EC50 of 35 nM for T cell activation.
    HBV/HDV-IN-2
  • HY-121850
    Rolicyprine
    		Inhibitor
    Rolicyprine (EX-4883) is an antidepressant with neuroprotective activity. Rolicyprine can improve depressive symptoms and promote neuroregeneration. Rolicyprine also shows potential effectiveness for anxiety suppression.
    Rolicyprine
  • HY-162795
    HBV-IN-47
    		Inhibitor
    HBV-IN-47 (compound 4a) is a capsid assembly regulator with inhibitory activity against hepatitis B virus (HBV). HBV-IN-47 exhibits strong anti-HBV activity in HepAD38 cells with low toxicity (EC50=0.24 μM). HBV-IN-47 can be used for the study of chronic hepatitis B (CHB).
    HBV-IN-47
  • HY-N3861
    Erythrocentaurin
    		Inhibitor
    Erythrocentaurin, a natural compound, is a new class of hepatitis B virus inhibitor.
    Erythrocentaurin
  • HY-145638C
    Xalnesiran sodium scrambled negative control
    		Inhibitor
    Xalnesiran sodium scrambled negative control is the sequence scrambled negative control of Xalnesiran sodium.
    Xalnesiran sodium scrambled negative control
  • HY-129923R
    (R)-Omeprazole sodium (Standard)
    		Inhibitor
    (R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
    (R)-Omeprazole sodium (Standard)
  • HY-113308S
    Taurolithocholic acid-d5
    		Inhibitor
    Taurolithocholic acid-d5 is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
    Taurolithocholic acid-d<sub>5</sub>
  • HY-B0250S
    Lamivudine-15N,d2
    		Inhibitor
    Lamivudine-15N,d2 is 15N and deuterated labeled Lamivudine (HY-B0250). Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
    Lamivudine-<sup>15</sup>N,d<sub>2</sub>
  • HY-148172
    L-Fd4A
    		Inhibitor
    L-Fd4A is an adenine derivative. L-Fd4A has anti-human immunodeficiency virus (HIV) (EC50=1.5 μM) and anti-hepatitis B virus (HBV) (EC50=1.7 μM) activity. L-Fd4A has low cytotoxicity.
    L-Fd4A
  • HY-177654A
    Ozisiran sodium
    		Inhibitor
    Ozisiran sodium, a siRNA, is a hepatitis B virus (HBV) RNA transcript reducer with antiviral activity.
    Ozisiran sodium
  • HY-106205
    Di-Val-L-dC
    		Inhibitor
    Di-Val-L-dC, a prodrug of L-deoxycytidine, is a selective and specific anti-HBV agent.
    Di-Val-L-dC
  • HY-P4043
    Hepatitis b virus pre-s region (120-145)
    		Inhibitor
    Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg.
    Hepatitis b virus pre-s region (120-145)
  • HY-125719
    Clevudine triphosphate
    		Inhibitor
    Clevudine triphosphate is a thymidine analog. Clevudine triphosphate has anti-human hepatitis B virus (HBV) activity.
    Clevudine triphosphate
  • HY-170605
    BA-AZT1
    		Inhibitor
    BA-AZT1 is the inhibitor for HBV polymerase and sodium taurocholate cotransporting polypeptide (NTCP). BA-AZT1 inhibits the secretion of viral capsid protein HBsAg and HBeAg with IC50 of 0.65 µM and 13.42 µM, inhibits the HBV DNA replication with an IC50 of 0.70 µM.
    BA-AZT1
Cat. No. Product Name / Synonyms Application Reactivity